124433-70-1

Basic information

• Product Name: 2-Pyridinesulfonamide,6-fluoro-(9CI)
• Synonyms: 2-Pyridinesulfonamide,6-fluoro-(9CI);6-Fluoro-2-Pyridinesulfonamide;6-Fluoropyridine-2-sulfonamide
• CAS NO: 124433-70-1
• Molecular Formula: C₅H₅FN₂O₂S
• Molecular Weight: 176.1688032
• Product Categories: SULFONAMIDE
• Mol File: 124433-70-1.mol

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2-Pyridinesulfonamide,6-fluoro-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Pyridinesulfonamide,6-fluoro-(9CI)(124433-70-1)
• EPA Substance Registry System: 2-Pyridinesulfonamide,6-fluoro-(9CI)(124433-70-1)

Safety Data

• Hazardous Substances Data: 124433-70-1(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry:
2-Pyridinesulfonamide,6-fluoro-(9CI) is used as a research compound for the development of new drugs, particularly those targeting carbonic anhydrase enzymes. The sulfonamide group in this compound allows for interactions with the active site of these enzymes, potentially leading to the inhibition of their activity.
Used in Pharmaceutical Research:
2-Pyridinesulfonamide,6-fluoro-(9CI) is used as a starting material or intermediate in the synthesis of novel pharmaceutical agents. The presence of the fluorine atom may provide unique properties to the compound, such as increased lipophilicity or metabolic stability, which can be advantageous in drug design.
Used in Drug Development:
2-Pyridinesulfonamide,6-fluoro-(9CI) is used as a potential candidate for the development of new therapeutic agents. Further research and testing would be needed to fully understand the potential uses and effects of this compound, including its efficacy, safety, and pharmacokinetic properties.

Upstream product

• 128583-07-3 6-fluoropyridine-2-sulfonyl chloride 
• 1513-65-1 2,6-difluoro pyridine 
• 124433-69-8 N-(1,1-dimethylethyl)-6-fluoro-2-pyridinesulfonamide 

Downstream Products

• 124433-71-2 6-(methylamino)pyridine-2-sulfonamide 

Relevant articles and documents

MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical composi

MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.

N-(PYRIDIN-2-YLSULFONYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF A CFTR MEDIATED DISEASE

The invention relates to heterocyclic compounds of the formula (I), in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.

N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE

The invention relates to heterocyclic compounds of the formula (I) in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.

MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.

Modulators of Cystic Fibrosis Transmembrane Conductance Regulator

The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.

COMPOUNDS FOR THE TREATMENT AND PREVENTION OF INFLUENZA

A compound of formula (I) as well as pharmaceutically acceptable salt thereof, wherein R1 to R4 and Ar are as defined in description and in claims, can be used as a medicament.

COMPOUNDS FOR THE TREATMENT AND PREVENTION OF INFLUENZA

A compound of formula (I) as well as pharmaceutically acceptable salt thereof, wherein R1 to R4 and Ar are as defined in description and in claims, can be used as a medicament.

COMPOUNDS FOR THE TREATMENT AND PREVENTION OF INFLUENZA

A compound of formula (I) as well as pharmaceutically acceptable salt thereof, wherein R1 to R4 and Ar are as defined in description and in claims, can be used as a medicament.

Insecticidal compounds

The invention provides insecticidally active compounds of formula (I): STR1 wherein X is nitrogen or carbon bearing a hydrogen atom; R1 is a group of formula --S(O)n --Y, wherein Y is an optionally substituted heterocyclic ring conta